Medical Marijuana Reclassified to Schedule III
Acting Attorney General Todd Blanche ordered FDA-approved and state-licensed medical marijuana placed in Schedule III, easing research barriers and federal restrictions.
Objective Facts
On April 23, 2026, Acting Attorney General Todd Blanche ordered FDA-approved marijuana products and state-licensed medical marijuana placed in Schedule III of the Controlled Substances Act. This moves licensed medical marijuana from Schedule I—reserved for drugs like heroin with no accepted medical use and high abuse potential—to Schedule III, which includes drugs like ketamine and Tylenol with codeine that have moderate-to-low dependence potential. The administration also announced an expedited hearing beginning June 29, 2026, to consider broader rescheduling of all marijuana. The move allows cannabis businesses to deduct ordinary business expenses previously disallowed under tax code, potentially altering economics for producers and distributors. Rescheduling is expected to accelerate medical research on cannabis and help fast-track research by reducing federal barriers that universities and hospitals have faced.
Left-Leaning Perspective
Adam J. Smith, executive director of the Marijuana Policy Project—the nation's leading cannabis policy reform organization—praised the reclassification as "a historic move towards sanity in cannabis policy" that opens doors to medical research and fairer tax treatment for the regulated industry. Congressman Steve Cohen welcomed the Department of Justice decision but emphasized that more must be done, stating that the order "is limited in its application since it doesn't affect recreational marijuana possession under federal criminal law, nor remove the disproportionately harsh life-altering criminal penalties associated with it." NORML's Deputy Director Paul Armentano called today's order "a historical reversal in federal cannabis policy" that "validates the experiences of tens of millions of Americans, as well as those of tens of thousands of physicians, who have long recognized that cannabis possesses legitimate medical utility." Left-leaning advocates emphasize that while the reclassification advances research and provides immediate tax relief to medical marijuana operators, it leaves critical gaps unaddressed. Smith notes that Schedule III status "stops short of the systemic change we need" and "does nothing to end hundreds of thousands of possession arrests each year, nor does it do anything to fix the untenable, ongoing disconnect between federal prohibition and the regulated state markets." Left-leaning coverage downplays criminal justice concerns by focusing heavily on tax benefits and research opportunities while giving less attention to the persistence of federal criminalization for simple possession and the practical barriers state-legal operators still face when accessing banking services.
Right-Leaning Perspective
Conservative Playlist acknowledged the reclassification reflects "state-level experimentation that has outpaced federal policy" and that "President Trump has prioritized patient outcomes and scientific inquiry over outdated prohibitions that treated cannabis identically to the most dangerous narcotics." However, prominent GOP opponents include House Speaker Mike Johnson of Louisiana, Senate Majority Whip John Barrasso, and Rep. Andy Harris of Maryland (chair of the Freedom Caucus), who all urged Trump to reject the reclassification. Senator Ted Budd argued that rescheduling would have "detrimental effects on the health and safety of Americans, especially our nation's youth," citing well-documented negative health impacts including "increased risk of heart attack, stroke, psychotic disorders, addiction and hospitalization." Right-leaning critics frame Schedule III reclassification as reckless capitulation to a profit-driven industry rather than sound drug policy. Conservative commentary warns that the left has "romanticized marijuana as harmless recreation, downplaying addiction risks, cognitive impacts on developing brains, and its role as a gateway substance for many," and argues that "federal reclassification risks sending mixed signals in a culture already battling opioid crises, declining mental health, and family breakdown." Smart Approaches to Marijuana, an anti-legalization group, stated it will "take legal action immediately" against the order, arguing that "the only thing today's decision advances are the interests of an addiction-for-profit industry." Right-leaning coverage focuses on youth vulnerability and health risks while emphasizing that schedule III status doesn't fully legalize cannabis—a point they use to question why the administration needed to act at all.
Deep Dive
The effort to downgrade marijuana's classification has been discussed and attempted by several administrations, but none were successful in finalizing a rule until now. Former President Joe Biden initiated a new attempt in the last year of his presidency, but it wasn't completed before he left office. The Biden Justice Department proposed reclassification, eliciting nearly 43,000 formal public comments. Trump ordered that process to move along as quickly as legally possible, and Acting Attorney General Todd Blanche's April 23 order sidestepped the traditional review process by relying on a provision of federal law that allows the attorney general to determine appropriate classification for drugs regulated under an international treaty. Despite Trump's December 2025 executive order directing swift reclassification, at least 20 Republican senators remain on record opposing rescheduling, and some are staunch Trump allies. Some conservatives acknowledge the reclassification reflects practical recognition that state-level experimentation has outpaced federal policy and that Trump prioritized patient outcomes over outdated prohibitions." However, they argue the left has "romanticized marijuana as harmless" while downplaying risks, and that reclassification risks "sending mixed signals in a culture already battling opioid crises." The left acknowledges research benefits but emphasizes that Schedule III leaves the federal-state conflict unresolved and hundreds of thousands under criminal threat. What happens next hinges on the expedited hearing scheduled to begin June 29, 2026, which will evaluate broader rescheduling of all marijuana—not just medical products—to Schedule III. Legal challenges are anticipated; opponents like Smart Approaches to Marijuana have already vowed to challenge the order in federal court. The June hearing will determine whether Trump's administration can extend reclassification beyond state-licensed medical products to cover recreational cannabis, a step that would face even fiercer GOP resistance but could significantly reshape federal drug policy.